Gilead
![Gilead_Sciences_Logo_white background[71].png](https://ics.ac.uk/static/ed9724eb-3628-438c-ae1c70a32d1a291c/emssponsorlogo_e34c3764bbafbd210abb1698e6c1232d_4a7c7e45a350/GileadSciencesLogowhite-background71.png)
Profile
Gilead Sciences Limited is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.
Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at ICS SOA 2023 except for the Gilead organised and funded symposia.
SOA23 roles
- Gilead are Principal Sponsors of SOA23 and can be found at stand 40
- Join Professor Andrew Ustianowski for their talk, Why COVID antivirals are still relevant to an ICU physician? being held on day 2 (28.6.23), stream 3 - 9:15am - 9:50am
- Join Lisa Nwankwo for their talk: One step ahead: Pharmaceutical considerations when treating a patient with invasive fungal disease, being held on day 2 (28.6.23), stream 3 - 9:55am - 10:30